Healthcare / Drug Manufacturers - Specialty & GenericKuala Lumpur
$3.79
+0.04 (+1.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $21.0M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$562M
P/E
14.6x
↓EV/EBITDA
8.2x
↓ROE
15.2%
↑Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.5%
FCF CAGR
-27.9%
FCF margin
9.1%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $230.8M · net income $42.5M · FCF $21.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $230.8M | $230.8M | $226.6M | $242.2M | $207.9M |
| Net Income | $42.5M | $42.5M | $44.6M | $65.2M | $62.1M |
| EBITDA | $65.0M | $65.0M | $70.8M | $80.9M | $73.5M |
| EPS | 0.29 | 0.29 | 0.30 | 0.44 | 0.42 |
| Gross Margin | — | — | 73.4% | 74.2% | 75.4% |
| Operating Margin | 21.3% | 21.3% | 21.8% | 25.0% | 26.7% |
| Net Margin | 18.4% | 18.4% | 19.7% | 26.9% | 29.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.03 |
| Current Ratio | 2.57 | 2.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $21.0M | $21.0M | $15.6M | $40.0M | $56.2M |
| Returns | |||||
| ROE | 15.2% | 15.2% | 16.2% | 24.1% | 25.4% |
| Valuation | |||||
| P/E | 14.58 | 14.58 | 14.30 | 11.78 | 9.34 |
| EV/EBITDA | 8.19 | 8.19 | 8.94 | 9.41 | 7.69 |
| P/B | 2.01 | 2.01 | 2.32 | 2.83 | 2.38 |
| Growth & Yield | |||||
| Revenue Growth | 1.9% | 1.9% | -6.5% | 16.5% | — |
| EPS Growth | -4.8% | -4.8% | -31.8% | 5.1% | — |
| Dividend Yield | 5.8% | 5.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
5.5%
EPS terminal req.
$0.34
Spread vs growth
-10.3%
5Y implied EPS CAGR
7.3%
EPS terminal req.
$0.41
Spread vs growth
-12.0%
10Y implied EPS CAGR
8.6%
EPS terminal req.
$0.66
Spread vs growth
-13.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.0%
Start / end P/E
13.7x → 13.2x
EPS bridge
0.30 → 0.29
Residual
+0.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.